Frazier's departure was later followed by a string of executive resignations from the manufacturing council this week before Trump announced Wednesday he would disband it.
Also, CytomX Therapeutics brings in $80 million, Vertera Spine won FDA 510(k) clearance and John Boehner is stalling on a deal that could potentially create massive increases in Medicare premiums.
At the J.P. Morgan Healthcare Conference this week some of the biggest names in healthcare gathered to discuss the state of the biopharmaceuticals sector. Amidst all of the commotion, some executives took a moment to tell CNBC‘s Meg Tirrell which CEO (in any industry) they’d most like to trade places with if given the chance. […]
Merck will follow big pharma’s standard MO of looking elsewhere to bring new assets in-house, CEO Kenneth Frazier said at this week’s J.P. Morgan healthcare investing conference. “As we move into 2015, we will continue to rigorously sharpen our focus, and find best external assets to fuel growth,” Frazier said, adding that Merck is on track to […]